Oramed Pharmaceuticals (ORMP) Net Margin (2016 - 2025)

Oramed Pharmaceuticals' Net Margin history runs 8 years deep, the most recent figure standing at 382.1% for Q1 2025.

• Quarterly Net Margin changed N/A year-over-year to 382.1% in Q1 2025, while the trailing twelve-month figure through Dec 2025 was 3760.1% (changed N/A YoY) and the FY2025 annual result came in at 3760.1%, changed N/A from the prior year.
• Net Margin was 382.1% for Q1 2025 at Oramed Pharmaceuticals, down from 194.81% in the prior quarter.
• Across five years, Net Margin topped out at 194.81% in Q2 2023 and bottomed at 1565.32% in Q1 2022.
• A 4-year average of 920.42% and a median of 928.95% in 2022 frame the typical range for Net Margin.
• Peak annual rise in Net Margin reached 136795 bps in 2023, while the deepest fall reached 105556 bps in 2023.
• Oramed Pharmaceuticals' Net Margin stood at 822.72% in 2021, then plunged by 57 bps to 1290.71% in 2022, then jumped by 85 bps to 194.81% in 2023, then plunged by 96 bps to 382.1% in 2025.
• Business Quant data shows ORMP's Net Margin at 382.1% in Q1 2025, 194.81% in Q2 2023, and 509.76% in Q1 2023.